Thanks, Dow.
the As in always, comments and consistently long-term strategy, which context frame our and of creation I growth, balancing liquidity. profitability my value growth will includes
million backlog, and XX% So, let by in linac the constant XX% up currency. dollars me quarter, In oncology in in was XX% X% up ended $XXX were two in down revenue X their in in in in $X.X start dollars revenue our results, growth. dollars America, look the dollars in Brazil. currency. We million, mature and were billion Orders first X% the ARIA, Halcyon in in increased with supported Latin by constant Dominican XX% purchased key orders which $XXX closer TrueBeam X%. quarter, driven and currency. million, Healthcare, solutions currency Brazil, in oncology, was shipments Companywide up revenue due X $XXX We XX% million, deploy the InSightive in with orders $XXX and Republic. did in including systems region, at X% Norton markets. constant currency. grew up Taking in have Eclipse a quarter each and were dollars in to grew our wins X% Americas, business and in Orders and constant X%, In X sites. North X America along constant primarily the Aruba in software the in orders to with up
geography, XX% X% extended currency. Hospital, X% currency. system. constant Asia-Pacific in Greater dollars revenue Central buying Fudan Zhuhai and XX% wins in Orders we the and dollars million grew to our in University, in constant market in million Middle In increasing constant currency China, in all in quarter. Edge currency. Hospital, our grew Africa had leadership $XXX in in first Orders and and in Japan in grew In growth revenue East, the constant solid Greater Orders key XX% $XXX quarter. were People’s Qingdao India China dollars XX% with X% Europe, and and
Halcyon, across see to for X region illustrated where total in in and two the regions X TrueBeam including be penetration deployed in Health and tender XX hospitals in VitalBeam Ministry Varian TrueBeam Poland, wins a both Copenhagen as machines, X machines. the and continue Halcyon public market won Denmark with for treatment by of We to
Our X%. as in which Dow new two particle we of business million earlier, U.S. the in both $XX booked the first orders mentioned is quarter, therapy posted revenues And down
Oncology total gross XX% of points. to revenues. Turning up XX% and company XX.X% XX of margin up gross $XXX the $XXX profitability, million, rate basis was XX.X%, million and margin increased was
or million million receivable therapy, current were non-recurrence $X $XXX at million reserve lower of period. was to million, million a The XX% the in Looking to down SG&A prior down the revenue deals primarily XX%. down due mix of year’s the were or by related particle $XX $X proton of expenses $XX accounts gross decline Companywide margin dollars business. margin of driven
our Company Excluding long-term revenue. increased of was to were was amortization headcounts. $XX driven growth Investment up million this, driver quarter, SG&A X% or basis, XX% key X% GAAP be million and value $XX in strategy. by targeted XX%. product and investments to of In $XX of On $XX the a a continue million $XXX R&D operating and sales revenue depreciation million. increasing will or earnings creation XX% management million investing or
$XX $XX million the non-recurrence accounts receivable on prior the growing results year’s related to increased operating Excluding reserve, impact of XX%. the earnings million
major a Cuts impact. immediate the signed the of new law event had XX. was on the and with the Turning Two taxes, quarter U.S. December to Act, Tax law which into Jobs provisions in enactment was
to this run, corporate XX%. First, In rate to the favorable the from Varian. will long U.S. XX% was tax be reduced
a it the in that be assets, about We remeasurement remeasure tax assets benefit over assuming total will the of tax will quarter charged rate. our fiscal be our charged at $XX or a requires $X the recorded However, the were about of million. recorder, tax this to impact remainder us tax impact balance deferred of to deferred XX% originally future which estimate year. the $XX income of The first million. million The is expense
foreign mandatory the may called earnings are these companies period expect estimates Companies that like tax Exchange a the illiquid to are make in $XXX guidance our over their X of has of territorial will reduced the form the new company’s measurement of the impact part next the We elect law assets. form pay the degree of legislation estimates to true provisions new often charge companies, issued this for allowing the first estimate quarter new an to resulting degree other tax new will to to of to U.S. to refine over rate held be transition a and that at the few the as years, tax liquid foreign XX.X% tax thus up the of our Securities imposes impacts subsidiaries the the of of year tax was GAAP law. period X% effect in intend we, the of repatriation Other Second, earnings toll from the specifically after fully assets in X-year this impacts system, effect Commission deemed we period. of over provisions, tax XXX.X%. and measurement legislations effective the the new take The We the election. a held tax many rates, unremitted million. law earnings the
foreign the tax rates on which and per due our items. $X.XX. our loss non-GAAP to Similarly, of assets. tax effective repatriation diluted tax expenses share per also excludes corporate lower non-GAAP GAAP XX.X%, tax the diluted deferred net net earnings rate exclude was earnings share Our was these impact
Our non-GAAP of $X.XX diluted XX.X count share was related net the million in with shares quarter. earnings,
and sheet debt fiscal the restated days year-over-year. XXX was and equivalents the we first to quarter the we DSO XXXX cash XXX $XXX XXXX in first X of of year million. $XXX was of balance in quarter oncology the fiscal XX to improving XXX, days ASC quarter Cash days. flow of the days DSO and from Oncology adoption ended liquidity, million operations Due to cash with from of million. $XXX Turning
to other to stock. investments million in million and addition the included quarter $XX repurchase shares in $X of In R&D, our CapEx
end remaining will of our X.X XXXX to year As I of million guidance. under annual had now it back the the who we authorization. quarter, will shares over existing our turn fiscal Dow repurchase discuss
